Clinical trial

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

NCT02453009

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-10-01

PhasePHASE2

Study timeline

Study start (actual)2014-10-01Date precision: month

Registry last updated2024-05-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostatic Neoplasmsunresolved

Interventions

DocetaxelDRUG · verified · RxNorm: docetaxel

PrednisoneDRUG · verified · RxNorm: prednisone

EnzalutamideDRUG · verified · RxNorm: enzalutamide

Sponsors & collaborators

Santa Chiara Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02453009 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.